BACKGROUND: In this phase 1/2 study, the authors tested the hypothesis that single-fraction stereotactic body radiotherapy (SBRT) for previously unirradiated spinal metastases is a safe, feasible, and efficacious treatment approach. METHODS: All patients were evaluated by a multidisciplinary team. Spinal magnetic resonance imaging studies were obtained before treatment and at regular intervals to define both target volume and response to treatment. SBRT was delivered to a peripheral dose of 16 to 24 grays in a single fraction while limiting the dose to the spinal cord. Higher doses were used for renal cell histology. The National Cancer Institute Common Toxicity Criteria 2.0 and McCormick neurologic function score were used as toxicity assessment tools. RESULTS: In total, 61 patients who had 63 tumors of the noncervical spine were enrolled and received SBRT between 2005 and 2010 on a prospective, phase 1/2 trial at The University of Texas M. D. Anderson Cancer Center. The mean follow-up was 20 months. The actuarial 18-month imaging local control rate for all patients was 88%, the actuarial 18-month overall survival rate for all patients was 64%, and the median survival for all patients was 30 months. No significant differences in outcomes were noted with respect to tumor histology or SBRT dose. Two patients experienced radiation adverse events (grade 3 or higher). The actuarial rate of 18-month freedom from neurologic deterioration from any cause was 82%. CONCLUSIONS: Data from this phase 1/2 trial supported an expanded indication for SBRT as first-line treatment of spinal metastases in selected patients. The authors concluded that additional studies that can prospectively identify predictive factors for spinal cord toxicity after SBRT are warranted to minimize the incidence of this serious yet rare complication.
BACKGROUND: In this phase 1/2 study, the authors tested the hypothesis that single-fraction stereotactic body radiotherapy (SBRT) for previously unirradiated spinal metastases is a safe, feasible, and efficacious treatment approach. METHODS: All patients were evaluated by a multidisciplinary team. Spinal magnetic resonance imaging studies were obtained before treatment and at regular intervals to define both target volume and response to treatment. SBRT was delivered to a peripheral dose of 16 to 24 grays in a single fraction while limiting the dose to the spinal cord. Higher doses were used for renal cell histology. The National Cancer Institute Common Toxicity Criteria 2.0 and McCormick neurologic function score were used as toxicity assessment tools. RESULTS: In total, 61 patients who had 63 tumors of the noncervical spine were enrolled and received SBRT between 2005 and 2010 on a prospective, phase 1/2 trial at The University of Texas M. D. Anderson Cancer Center. The mean follow-up was 20 months. The actuarial 18-month imaging local control rate for all patients was 88%, the actuarial 18-month overall survival rate for all patients was 64%, and the median survival for all patients was 30 months. No significant differences in outcomes were noted with respect to tumor histology or SBRT dose. Two patients experienced radiation adverse events (grade 3 or higher). The actuarial rate of 18-month freedom from neurologic deterioration from any cause was 82%. CONCLUSIONS: Data from this phase 1/2 trial supported an expanded indication for SBRT as first-line treatment of spinal metastases in selected patients. The authors concluded that additional studies that can prospectively identify predictive factors for spinal cord toxicity after SBRT are warranted to minimize the incidence of this serious yet rare complication.
Authors: Roy A Patchell; Phillip A Tibbs; William F Regine; Richard Payne; Stephen Saris; Richard J Kryscio; Mohammed Mohiuddin; Byron Young Journal: Lancet Date: 2005 Aug 20-26 Impact factor: 79.321
Authors: Samuel Ryu; Jian-Yue Jin; Ryan Jin; Jack Rock; Munther Ajlouni; Benjamin Movsas; Mark Rosenblum; Jae Ho Kim Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: Eric L Chang; Almon S Shiu; Ming-Fwu Lii; Laurence D Rhines; Ehud Mendel; Anita Mahajan; Jeffrey S Weinberg; Leni A Mathews; Barry W Brown; Moshe H Maor; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2004-08-01 Impact factor: 7.038
Authors: Eric L Chang; Almon S Shiu; Ehud Mendel; Leni A Mathews; Anita Mahajan; Pamela K Allen; Jeffrey S Weinberg; Barry W Brown; Xin Shelly Wang; Shiao Y Woo; Charles Cleeland; Moshe H Maor; Laurence D Rhines Journal: J Neurosurg Spine Date: 2007-08
Authors: Zain A Husain; Arjun Sahgal; Eric L Chang; Pejman Jabehdar Maralani; Charlotte D Kubicky; Kristin J Redmond; Charles Fisher; Ilya Laufer; Simon S Lo Journal: CNS Oncol Date: 2017-07-18
Authors: Morten H Suppli; Per Munck Af Rosenschold; Helle Pappot; Benny Dahl; Søren S Morgen; Ivan R Vogelius; Svend A Engelholm Journal: J Radiosurg SBRT Date: 2016
Authors: Pretesh R Patel; John Kirkpatrick; Joseph K Salama; John Nelson; Gloria Broadwater; Karen Allen; Robert Clough; Fang-Fang Yin; Zhiheng Wang; Zheng Chang; Christopher Kelsey; A Paiman Ghafoori Journal: J Radiosurg SBRT Date: 2014
Authors: Frederick Mantel; Stefan Glatz; André Toussaint; Michael Flentje; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-06-27 Impact factor: 3.621